Rezolute Inc RZLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RZLT is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $3.43
- Day Range
- $3.38–3.69
- 52-Week Range
- $0.72–3.69
- Bid/Ask
- $3.39 / $5.66
- Market Cap
- $142.05 Mil
- Volume/Avg
- 333,631 / 331,209
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 51
- Website
- https://www.rezolutebio.com
Comparables
Valuation
|
Metric
|
RZLT
|
CRNX
|
PNT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 11.36 |
Price/Book Value | 1.53 | 5.44 | 3.12 |
Price/Sales | — | 622.39 | 5.50 |
Price/Cash Flow | — | — | 13.90 |
Price/Earnings
RZLT
CRNX
PNT
Financial Strength
|
Metric
|
RZLT
|
CRNX
|
PNT
|
|---|---|---|---|
Quick Ratio | 11.56 | 12.92 | 9.01 |
Current Ratio | 12.00 | 13.07 | 9.14 |
Interest Coverage | — | — | — |
Quick Ratio
RZLT
CRNX
PNT
Profitability
|
Metric
|
RZLT
|
CRNX
|
PNT
|
|---|---|---|---|
Return on Assets (Normalized) | −39.69% | −38.81% | 20.67% |
Return on Equity (Normalized) | −42.65% | −44.79% | 23.56% |
Return on Invested Capital (Normalized) | −46.57% | −45.62% | 23.38% |
Return on Assets
RZLT
CRNX
PNT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lnbwmkmhcd | Btlvv | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xhvxffw | Xhtzsy | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zxwfvldxc | Tcnynp | $98.8 Bil | |
MRNA
| Moderna Inc | Qcttzflt | Qqmfp | $38.8 Bil | |
ARGX
| argenx SE ADR | Zgqcskh | Fdqd | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Zrjbykkt | Myh | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cwkshvgl | Zzgjnq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mthfrrpkd | Rrsqk | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vgrdpdnmg | Zckswp | $12.4 Bil | |
INCY
| Incyte Corp | Yjbtstzz | Hpzbddq | $11.9 Bil |